APVONot HalalF
Unlock full report, free

Is Aptevo Therapeutics (APVO) Stock Halal?

Compliance Status

Not Halal

Screened on Nov 12, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Aptevo Therapeutics Inc. (APVO) halal? Not Halal. Based on AAOIFI screening, Aptevo Therapeutics Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Aptevo Therapeutics Inc. (APVO) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 12, 2026. Source: https://halalscreener.app/en/stock/APVO

Business activity

What the company sells is permissible.

Passed

Company debt

Over the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

155.2% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding APVO

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Share this verdict

A receipt-style image with the math on it, so whoever you send it to can check it.

Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

NASDAQHealthcareUS

$0.59

Market Cap: 1.3M

Screened on a market cap of 2.7M

Get an email if APVO's halal status changes

We re-screen Aptevo Therapeutics Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Interest-bearing debt is 155.2% of market cap, over the 30% AAOIFI limit.
  • Interest-bearing deposits are over the 30% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Nov 12, 2026
AI Compliance InsightProSee plans
Revenue BreakdownProSee plans

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: FMP
Free · No credit card required

Know the day APVO's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Aptevo Therapeutics Inc. (APVO) halal to invest in?
Aptevo Therapeutics Inc. (APVO) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Aptevo Therapeutics Inc. get a F compliance rating?
Aptevo Therapeutics Inc. (APVO) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 155.2% (limit 30%); interest-bearing deposits over the 30% limit; prohibited income well clear of the 5% limit. The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Aptevo Therapeutics Inc.'s Shariah verdict?
Aptevo Therapeutics Inc.'s verdict is recalculated at every re-screen, including the one that follows each new quarterly or annual report. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Aptevo Therapeutics Inc. re-screened for Shariah compliance?
Aptevo Therapeutics Inc. (APVO) is screened from the latest financial statements on record, currently those for fiscal Q2 2026. The 500 largest US-listed companies, and every stock on a HalalScreener watchlist or portfolio, are re-screened daily against the current market cap; every other stock at least once a week. When the company files a new quarterly or annual report with the SEC, it is re-screened from that filing: we check the SEC's filing feed every 15 minutes and the earnings calendar every day. Last screened: Nov 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.